Phoenix Life Sciences International Limited
PLSI · OTC
2/28/2019 | 11/30/2018 | 8/31/2018 | 5/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.00 | 0.01 |
| FCF Yield | -84.56% | -54.44% | -87.39% | -0.01% |
| EV / EBITDA | 1.00 | -0.32 | -12.09 | -2.81 |
| Quality | ||||
| ROIC | -14.32% | -24.62% | 1.53% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -1.51 | 0.19 | 0.91 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 43.47% | -104.23% | -597,706.67% | 13.46% |
| Safety | ||||
| Net Debt / EBITDA | -0.83 | 0.00 | 0.03 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | -1.00 | -0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |